Indonesia races to contain diphtheria outbreak ahead of 2018 Asian Gam

Health authorities in Jakarta kicked off a special immunization program on Monday to rein in an

 3 Views    0 Like    0 comment

GSK's new pharma head on lookout for cancer deals to boost pipeline

GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its ne

 2 Views    0 Like    0 comment

Roche: Tecentriq cocktail slows kidney cancer progression

Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advance

 0 View    0 Like    0 comment

Merck raises stakes in lung cancer as rivals close in

Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by play

 2 Views    0 Like    0 comment

Hospital operators in merger talks to form U.S. industry leader: WSJ

Ascension Health and Providence St. Joseph Health are in talks about a merger between the two Catholic non-profits that would create the largest U.S. hospital

 5 Views    0 Like    0 comment

Hospital operators in merger talks to create U.S. industry leader: WSJ

Ascension Health and Providence St. Joseph Health are in discussions about a merger that would create the largest hospital chain in the United States, the Wall

 2 Views    0 Like    0 comment

Exclusive: Philippines defied experts' advice in pursuing dengue immun

As she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation's then health secretary Janette

 4 Views    0 Like    0 comment

France orders international recall of Lactalis baby formula

France has ordered banned the sale and ordered a recall of several baby formula milk and baby food products made by French dairy giant Lactalis after the disco

 4 Views    0 Like    0 comment

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel th

 4 Views    0 Like    0 comment

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio In

 3 Views    0 Like    0 comment

Novartis CAR-T therapy leads to durable response in lymphoma study

Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to res

 5 Views    0 Like    0 comment

Roche lymphoma drug drives high remission rate, longer survival: study

An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood

 4 Views    0 Like    0 comment